retatrutide phase 3 data is showing 17% weight loss in 40 weeks with no plateau in sight.
I've been watching the pipeline for retatrutide and recently the first phase 3 results are seriously impressive. In the TRANSCEND-T2D-1 trial, the high-dose group (12 mg) lost an average of 36.6 pounds (16.8% of body weight) at 40 weeks. And here's the kicker: weight loss continued through the end of the treatment period with no plateau observed, meaning it might have kept going if the trial had lasted longer.
For comparison, tirzepatide's phase 3 trials showed about 15-20% weight loss over 72 weeks. Retatrutide is hitting those numbers in about half the time. The drug is still investigational and not yet FDA-approved, but if the full phase 3 data holds, it's going to be a major contender.